医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BestWeek Asia-Pacific: GCC Takaful Regulation Lags Behind Market Growth

2013年01月29日 AM05:55
このエントリーをはてなブックマークに追加


 

HONG KONG

While the takaful industry has been developing rapidly in the countries of the Gulf Cooperation Council, the development of takaful regulation varies significantly country by country, according to a new special report featured in BestWeek Asia-Pacific. As a result, the levels of policyholder protection differ from one state to another, which has created opportunities for takaful operators to pursue regulatory arbitrage.

Indeed, there is significant debate as to the right level of regulation. Market participants in some of the more demanding regimes consider the regulations to be stifling their companies. A.M. Best believes the solution is not less regulation but more consistent application of regulation throughout the region, which has the potential to provide sufficient policyholder protection, and thus safeguard the long-term viability of the takaful industry.

Also featured in BestWeek Asia-Pacific, a look at how widening health protection gaps in China are creating an opening and potential major role for private individual medical insurance to fill the gap. Health care spending is projected to grow from US$357 billion in 2011 to US$1 trillion in 2020, according to consultancy McKinsey & Co. Cigna Corp. told BestWeek Asia-Pacific the sustainability of the commercial group medical insurance market remains a big concern to many insurers in China, paving the way for private individual medical insurance to “play an important supplementary role” in health care reform.

The Jan. 29 edition is available at www.bestweek.com/asia and www.bestweek.com.

BestWeek is published by A.M. Best Co. for insurance professionals. To subscribe, visit www.ambest.com/sales/BestWeek.

BestWeek can be accessed on iPads and mobile devices at www.bestweek.com. On your iPad or mobile device, click on BestWeek digital to log in.

Founded in 1899, A.M. Best Co. is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2013 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

CONTACT

A.M. Best Co.
Iris Lai, +(852) 2827 3400
iris.lai@ambest.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高